Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction? Or A Drug Class Worth Reviving?

Ruth L. M. Cordiner, Ewan R. Pearson (Lead / Corresponding author)

Research output: Contribution to journalReview article

1 Citation (Scopus)
67 Downloads (Pure)

Abstract

The role of sulphonylureas (SUs) in modern clinical practice poses ongoing clinical debate. With the advent of newer agents in diabetes management, there is an increasing shift away from the prescribing of SUs, but not necessarily to more effective agents. This review provides a different perspective on the debate, reflecting in depth upon the physiology of SUs, drawing on insights gained from monogenic diabetes to highlight the potential benefit of lower doses of SUs, and the probable benefit of gliclazide over most other, if not all SUs, in terms of sulphonylurea failure and cardiovascular outcomes.
Original languageEnglish
Pages (from-to)761-771
Number of pages11
JournalDiabetes, Obesity & Metabolism
Volume21
Issue number4
Early online date24 Nov 2018
DOIs
Publication statusPublished - 11 Feb 2019

Keywords

  • cardiovascular disease
  • dose-response relationship
  • glucose metabolism
  • pharmacogenetics
  • sulphonylureas
  • type 2 diabetes

Fingerprint Dive into the research topics of 'Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction? Or A Drug Class Worth Reviving?'. Together they form a unique fingerprint.

  • Projects

    Cite this